# Study on dynamic alterations of plasma lipid profiles during disease progression in combined allergic rhinitis and asthma syndrome based on lipidomics

**Authors:** Yanmin Shi, Yiting Li, Zifan Cheng, JiaJia Wang, Suyun Li, Yang Xie

PMC · DOI: 10.3389/fimmu.2025.1666214 · Frontiers in Immunology · 2025-10-22

## TL;DR

This study tracks changes in lipid profiles across stages of allergic rhinitis and asthma, linking lipid metabolism to inflammation and potential treatment targets.

## Contribution

The study identifies stage-specific lipid metabolic changes in CARAS, linking them to inflammation and mucin expression.

## Key findings

- CARASa patients show elevated IgE and increased glycerolipids like triglycerides and ceramides.
- Chronic CARASb shows persistent dysregulation of sphingomyelins and membrane lipids.
- Lipid changes in CARASc correlate negatively with pro-inflammatory factors and mucins.

## Abstract

Combined allergic rhinitis and asthma syndrome (CARAS) involves complex interactions between inflammation and lipid metabolism. This study recruited 90 CARAS patients admitted to the First Affiliated Hospital of Henan University of Chinese Medicine from August 2023 to August 2024 (30 cases each for CARASa, CARASb and CARASc), along with 30 healthy controls (HC). We systematically profiled serum lipidomes across different CARAS stages and examined associations with inflammatory cytokines and mucins. Baseline characteristics were comparable among healthy controls (HC) and CARAS subgroups. CARAS patients in the acute phase (CARASa) exhibited elevated serum-specific IgE and fractional exhaled nitric oxide, indicating heightened allergic sensitization, while pulmonary function remained preserved. Lipidomic analysis revealed a pronounced shift from fatty acids to glycerolipids in CARASa, with upregulation of triglycerides, digalactosyldiacylglycerol, phosphatidylserines, phosphatidylethanolamines, and ceramides. CARASb (chronic persistence) showed persistent dysregulation of sphingomyelins, lysophosphatidylcholines, and membrane lipids, whereas CARASc (clinical remission) exhibited partial recovery with residual alterations in specific lipid classes. Correlation analysis indicated that fatty acid depletion strongly associated with glycerolipid accumulation. Pathway enrichment highlighted stage-dependent disturbances in fatty acid transport, GLP-1/incretin turnover, sphingolipid biosynthesis, and retinoid metabolism, reflecting metabolic-immune crosstalk. Notably, differential lipids (Digalactosyldiacylglycerol, phosphatidylethanolamines and phosphatidylserine) positively correlated with pro-inflammatory cytokines (TNF-α, IL-6) and mucins (MUC1, MUC5AC) in CARASa and CARASb groups. In the CARASc group, these differential lipids showed a negative correlation with pro-inflammatory factors and mucins. These findings define a trajectory of stage-specific lipid metabolic remodeling in CARAS, linking energy metabolism and membrane lipid changes to inflammatory activation and mucin expression, providing potential metabolic biomarkers and therapeutic targets.

## Linked entities

- **Proteins:** MUC1 (mucin 1, cell surface associated), MUC5AC (mucin 5AC, oligomeric mucus/gel-forming), TNF (tumor necrosis factor), IL6 (interleukin 6)
- **Chemicals:** digalactosyldiacylglycerol (PubChem CID 10724471), phosphatidylserines (PubChem CID 9547096), sphingomyelins (PubChem CID 44176376), lysophosphatidylcholines (PubChem CID 5311264)
- **Diseases:** allergic rhinitis (MONDO:0011786), asthma (MONDO:0004979)

## Full-text entities

- **Genes:** MUC5AC (mucin 5AC, oligomeric mucus/gel-forming) [NCBI Gene 4586] {aka MUC5, TBM, leB, mucin}, IGHE (immunoglobulin heavy constant epsilon) [NCBI Gene 3497] {aka IgE}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, mucin [NCBI Gene 100508689], MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** allergic (MESH:D004342), CARAS (OMIM:610906), inflammatory cytokines (MESH:D000080424), inflammation (MESH:D007249)
- **Chemicals:** retinoid (MESH:D012176), glycerolipid (-), phosphatidylserine (MESH:D010718), lysophosphatidylcholines (MESH:D008244), nitric oxide (MESH:D009569), ceramides (MESH:D002518), phosphatidylethanolamines (MESH:D010714), fatty acid (MESH:D005227), sphingomyelins (MESH:D013109), triglycerides (MESH:D014280), lipid (MESH:D008055), Digalactosyldiacylglycerol (MESH:C007388), sphingolipid (MESH:D013107)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12586177/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12586177/full.md

## References

35 references — full list in the complete paper: https://tomesphere.com/paper/PMC12586177/full.md

---
Source: https://tomesphere.com/paper/PMC12586177